Atlas Trials

A Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)

Clinical trial NCT04200456 · TERMINATED

Trial details

NCT number
NCT04200456
Sponsor
UCB Biopharma SRL
Status
TERMINATED
Phase
Phase 3
Study type
INTERVENTIONAL
Primary Immune Thrombocytopenia
Start date
2020-01-31
Primary completion
2022-03-21
Enrollment
33

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.